Pre-biopsy MRIs can help doctors diagnose and treat prostate cancer more accurately. Here’s when you should get one.

Millions of men could benefit from a new, faster prostate cancer scan. The quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer in clinical trials as the current 30- to ...

Prostate cancer is the second-leading cause of death among American men, killing one in 44. In the United States, 3.3 million men are survivors of prostate cancer, and the risk for developing the ...

A quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30–40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

A quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, ...

After a comprehensive two-year follow-up, researchers found that MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer significantly reduced long-term side effects and improved quality ...

In patients with biochemical failure after prostatectomy, about two thirds showed detectable local disease at restaging. Multiparametric MRI alone detected local lesions in over one third of patients ...

Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...

As part of the “Speaking Out” series, a radiation oncologist discusses the benefits of MRI-guided stereotactic body radiation therapy. Dr. Matthew Solhjem, a radiation oncologist with Providence ...

Millions of men could benefit from a new, faster prostate cancer scan. The quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer in clinical trials as the current 30- to ...